Cargando…

Metabolite Profile of Alzheimer’s Disease in the Frontal Cortex as Analyzed by HRMAS (1)H NMR

Background: Investigation on neurochemical changes in the frontal cortex in individuals with Alzheimer’s disease (AD) and different Apolipoprotein E (APOE) genotypes, using ex vivo solid-state high-resolution NMR analysis, may lead to a better understanding of the neurochemistry associated with AD a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yuzhong, Liu, Zhou, Ji, Bing, Liu, Lijian, Wu, Shaoxiong, Liu, Xiaowu, Wang, Silun, Wang, Liya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333733/
https://www.ncbi.nlm.nih.gov/pubmed/30687076
http://dx.doi.org/10.3389/fnagi.2018.00424
_version_ 1783387610056491008
author Zhang, Yuzhong
Liu, Zhou
Ji, Bing
Liu, Lijian
Wu, Shaoxiong
Liu, Xiaowu
Wang, Silun
Wang, Liya
author_facet Zhang, Yuzhong
Liu, Zhou
Ji, Bing
Liu, Lijian
Wu, Shaoxiong
Liu, Xiaowu
Wang, Silun
Wang, Liya
author_sort Zhang, Yuzhong
collection PubMed
description Background: Investigation on neurochemical changes in the frontal cortex in individuals with Alzheimer’s disease (AD) and different Apolipoprotein E (APOE) genotypes, using ex vivo solid-state high-resolution NMR analysis, may lead to a better understanding of the neurochemistry associated with AD as well as new AD-specific metabolite biomarkers that might potentially improve the clinical diagnosis of AD. Methods: Intact tissue samples of the frontal cortex were obtained from 11 patients and 11 age-matched non-demented controls. Metabolite profiles in all samples were analyzed ex vivo, using solid-state high-resolution magic angle spinning (HRMAS) 600 MHz (1)H nuclear magnetic resonance (NMR). A logistic regression analysis was used to rank metabolites based on their level of contribution in differentiating the AD patient tissues and the controls, and different AD-associated APOE genotypes (APOE ε4 vs. APOE ε3). Results: Tissue samples from the AD patients showed significantly lower NAA/Cr (p = 0.011), Ace/Cr (p = 0.027), GABA/Cr (p = 0.005), Asp/Cr (p < 0.0001), mI/Cr (p < 0.0001), and Tau/Cr (p = 0.021), and higher PCho/Cr (p < 0.0001), GPCho/Cr (p < 0.0001), and α&β-Glc/Cr (p < 0.0001) than the controls did. Specifically, a newly observed resonance at 3.71 ppm, referred to as α&β-Glc, was observed in 90.9% of the AD samples (10/11). Samples with APOE ε4 also exhibited higher PCho/Cr (p = 0.0002), GPCho/Cr (p = 0.0001), α&β-Glc/Cr (p < 0.0001), and lower Asp/Cr (p = 0.004) and GABA/Cr (p = 0.04) than the samples with APOE ε3 did. In the logistic regression analysis, PCho, GPCho, ASP, and α&β-Glc were found to be the most relevant metabolites for differentiating the AD patient tissues and the controls, and different APOE genotypes. Conclusion: HRMAS (1)H NMR with high spectral resolution and sensitivity offers a powerful tool to gain quantitative information on AD associated neurochemical changes. There are important neurochemical differences in the frontal cortex between the AD patient tissues and the controls, and between those with different APOE genotypes. The resonance (α&β-Glc) found at 3.71 ppm in the AD patient tissues may be further investigated for its potential in the diagnosis and monitoring of AD.
format Online
Article
Text
id pubmed-6333733
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-63337332019-01-25 Metabolite Profile of Alzheimer’s Disease in the Frontal Cortex as Analyzed by HRMAS (1)H NMR Zhang, Yuzhong Liu, Zhou Ji, Bing Liu, Lijian Wu, Shaoxiong Liu, Xiaowu Wang, Silun Wang, Liya Front Aging Neurosci Neuroscience Background: Investigation on neurochemical changes in the frontal cortex in individuals with Alzheimer’s disease (AD) and different Apolipoprotein E (APOE) genotypes, using ex vivo solid-state high-resolution NMR analysis, may lead to a better understanding of the neurochemistry associated with AD as well as new AD-specific metabolite biomarkers that might potentially improve the clinical diagnosis of AD. Methods: Intact tissue samples of the frontal cortex were obtained from 11 patients and 11 age-matched non-demented controls. Metabolite profiles in all samples were analyzed ex vivo, using solid-state high-resolution magic angle spinning (HRMAS) 600 MHz (1)H nuclear magnetic resonance (NMR). A logistic regression analysis was used to rank metabolites based on their level of contribution in differentiating the AD patient tissues and the controls, and different AD-associated APOE genotypes (APOE ε4 vs. APOE ε3). Results: Tissue samples from the AD patients showed significantly lower NAA/Cr (p = 0.011), Ace/Cr (p = 0.027), GABA/Cr (p = 0.005), Asp/Cr (p < 0.0001), mI/Cr (p < 0.0001), and Tau/Cr (p = 0.021), and higher PCho/Cr (p < 0.0001), GPCho/Cr (p < 0.0001), and α&β-Glc/Cr (p < 0.0001) than the controls did. Specifically, a newly observed resonance at 3.71 ppm, referred to as α&β-Glc, was observed in 90.9% of the AD samples (10/11). Samples with APOE ε4 also exhibited higher PCho/Cr (p = 0.0002), GPCho/Cr (p = 0.0001), α&β-Glc/Cr (p < 0.0001), and lower Asp/Cr (p = 0.004) and GABA/Cr (p = 0.04) than the samples with APOE ε3 did. In the logistic regression analysis, PCho, GPCho, ASP, and α&β-Glc were found to be the most relevant metabolites for differentiating the AD patient tissues and the controls, and different APOE genotypes. Conclusion: HRMAS (1)H NMR with high spectral resolution and sensitivity offers a powerful tool to gain quantitative information on AD associated neurochemical changes. There are important neurochemical differences in the frontal cortex between the AD patient tissues and the controls, and between those with different APOE genotypes. The resonance (α&β-Glc) found at 3.71 ppm in the AD patient tissues may be further investigated for its potential in the diagnosis and monitoring of AD. Frontiers Media S.A. 2019-01-09 /pmc/articles/PMC6333733/ /pubmed/30687076 http://dx.doi.org/10.3389/fnagi.2018.00424 Text en Copyright © 2019 Zhang, Liu, Ji, Liu, Wu, Liu, Wang and Wang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Zhang, Yuzhong
Liu, Zhou
Ji, Bing
Liu, Lijian
Wu, Shaoxiong
Liu, Xiaowu
Wang, Silun
Wang, Liya
Metabolite Profile of Alzheimer’s Disease in the Frontal Cortex as Analyzed by HRMAS (1)H NMR
title Metabolite Profile of Alzheimer’s Disease in the Frontal Cortex as Analyzed by HRMAS (1)H NMR
title_full Metabolite Profile of Alzheimer’s Disease in the Frontal Cortex as Analyzed by HRMAS (1)H NMR
title_fullStr Metabolite Profile of Alzheimer’s Disease in the Frontal Cortex as Analyzed by HRMAS (1)H NMR
title_full_unstemmed Metabolite Profile of Alzheimer’s Disease in the Frontal Cortex as Analyzed by HRMAS (1)H NMR
title_short Metabolite Profile of Alzheimer’s Disease in the Frontal Cortex as Analyzed by HRMAS (1)H NMR
title_sort metabolite profile of alzheimer’s disease in the frontal cortex as analyzed by hrmas (1)h nmr
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333733/
https://www.ncbi.nlm.nih.gov/pubmed/30687076
http://dx.doi.org/10.3389/fnagi.2018.00424
work_keys_str_mv AT zhangyuzhong metaboliteprofileofalzheimersdiseaseinthefrontalcortexasanalyzedbyhrmas1hnmr
AT liuzhou metaboliteprofileofalzheimersdiseaseinthefrontalcortexasanalyzedbyhrmas1hnmr
AT jibing metaboliteprofileofalzheimersdiseaseinthefrontalcortexasanalyzedbyhrmas1hnmr
AT liulijian metaboliteprofileofalzheimersdiseaseinthefrontalcortexasanalyzedbyhrmas1hnmr
AT wushaoxiong metaboliteprofileofalzheimersdiseaseinthefrontalcortexasanalyzedbyhrmas1hnmr
AT liuxiaowu metaboliteprofileofalzheimersdiseaseinthefrontalcortexasanalyzedbyhrmas1hnmr
AT wangsilun metaboliteprofileofalzheimersdiseaseinthefrontalcortexasanalyzedbyhrmas1hnmr
AT wangliya metaboliteprofileofalzheimersdiseaseinthefrontalcortexasanalyzedbyhrmas1hnmr